These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
246 related articles for article (PubMed ID: 30166531)
21. Multiclonal colorectal cancers with divergent histomorphological features and RAS mutations: one cancer or separate cancers? Lin MT; Zheng G; Tseng LH; Zhang P; Ling H; Azad N; Gocke CD; Montgomery E; Eshleman JR Hum Pathol; 2020 Apr; 98():120-128. PubMed ID: 32171651 [TBL] [Abstract][Full Text] [Related]
22. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA. Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474 [TBL] [Abstract][Full Text] [Related]
23. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients. Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725 [TBL] [Abstract][Full Text] [Related]
24. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer. Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442 [TBL] [Abstract][Full Text] [Related]
25. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525 [TBL] [Abstract][Full Text] [Related]
26. Morphologic and molecular characterization of traditional serrated adenomas of the distal colon and rectum. Wiland HO; Shadrach B; Allende D; Carver P; Goldblum JR; Liu X; Patil DT; Rybicki LA; Pai RK Am J Surg Pathol; 2014 Sep; 38(9):1290-7. PubMed ID: 25127095 [TBL] [Abstract][Full Text] [Related]
27. Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patients. Xu X; Huang F; Cao M; Chen X; Wang H; Jiang H; Yu Y; Shen M; Yang Y; Wang B; Liu T; Guo W J Clin Lab Anal; 2021 Sep; 35(9):e23818. PubMed ID: 34403504 [TBL] [Abstract][Full Text] [Related]
28. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues. Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390 [TBL] [Abstract][Full Text] [Related]
29. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Kim KM; Lee EJ; Ha S; Kang SY; Jang KT; Park CK; Kim JY; Kim YH; Chang DK; Odze RD Am J Surg Pathol; 2011 Sep; 35(9):1274-86. PubMed ID: 21836485 [TBL] [Abstract][Full Text] [Related]
30. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791 [TBL] [Abstract][Full Text] [Related]
31. Mutational Heterogeneity in Gausachs M; Borras E; Chang K; Gonzalez S; Azuara D; Delgado Amador A; Lopez-Doriga A; San Lucas FA; Sanjuan X; Paules MJ; Taggart MW; Davies GE; Ehli EA; Fowler J; Moreno V; Pineda M; You YN; Lynch PM; Lazaro C; Navin NE; Scheet PA; Hawk ET; Capella G; Vilar E Clin Cancer Res; 2017 Oct; 23(19):5936-5947. PubMed ID: 28645942 [No Abstract] [Full Text] [Related]
32. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma. Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974 [TBL] [Abstract][Full Text] [Related]
33. Identification of liquid biopsy-based mutations in colorectal cancer by targeted sequencing assays. Szász I; Kiss T; Mokánszki A; Koroknai V; Deák J; Patel V; Jámbor K; Ádány R; Balázs M Mol Cell Probes; 2023 Feb; 67():101888. PubMed ID: 36513244 [TBL] [Abstract][Full Text] [Related]
34. Role of circulating free DNA in evaluating clinical tumor burden and predicting survival in Chinese metastatic colorectal cancer patients. Xu X; Yu Y; Shen M; Liu M; Wu S; Liang L; Huang F; Zhang C; Guo W; Liu T BMC Cancer; 2020 Oct; 20(1):1006. PubMed ID: 33066758 [TBL] [Abstract][Full Text] [Related]
35. Circulating tumor DNA-based early detection of precancerous colorectal lesions using QClamp XNA-mediated real-time PCR. Chen S; Wang Y; Wang K; Zhang L; Zhang X Pharmazie; 2021 Dec; 76(12):606-610. PubMed ID: 34986957 [TBL] [Abstract][Full Text] [Related]
36. Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer. Lucchetti D; Zurlo IV; Colella F; Ricciardi-Tenore C; Di Salvatore M; Tortora G; De Maria R; Giuliante F; Cassano A; Basso M; Crucitti A; Laurenzana I; Artemi G; Sgambato A Sci Rep; 2021 Nov; 11(1):22686. PubMed ID: 34811396 [TBL] [Abstract][Full Text] [Related]
38. Somatic mutation detection using various targeted detection assays in paired samples of circulating tumor DNA, primary tumor and metastases from patients undergoing resection of colorectal liver metastases. Beije N; Helmijr JC; Weerts MJA; Beaufort CM; Wiggin M; Marziali A; Verhoef C; Sleijfer S; Jansen MPHM; Martens JWM Mol Oncol; 2016 Dec; 10(10):1575-1584. PubMed ID: 28949453 [TBL] [Abstract][Full Text] [Related]
39. Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. Sinicrope FA; Shi Q; Allegra CJ; Smyrk TC; Thibodeau SN; Goldberg RM; Meyers JP; Pogue-Geile KL; Yothers G; Sargent DJ; Alberts SR JAMA Oncol; 2017 Apr; 3(4):472-480. PubMed ID: 28006055 [TBL] [Abstract][Full Text] [Related]
40. Three molecular pathways model colorectal carcinogenesis in Lynch syndrome. Ahadova A; Gallon R; Gebert J; Ballhausen A; Endris V; Kirchner M; Stenzinger A; Burn J; von Knebel Doeberitz M; Bläker H; Kloor M Int J Cancer; 2018 Jul; 143(1):139-150. PubMed ID: 29424427 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]